Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Travere Therapeutics Inc (NASDAQ: TVTX) closed at $34.38 in the last session, down -0.38% from day before closing price of $34.51. In other words, the price has decreased by -$0.38 from its previous closing price. On the day, 1.15 million shares were traded. TVTX stock price reached its highest trading level at $35.15 during the session, while it also had its lowest trading level at $33.84.
Ratios:
We take a closer look at TVTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.75. In the meantime, Its Debt-to-Equity ratio is 4.48 whereas as Long-Term Debt/Eq ratio is at 4.40.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on October 31, 2025, Reiterated its Buy rating but revised its target price to $48 from $34 previously.
Citigroup reiterated its Buy rating for the stock on June 11, 2025, while the target price for the stock was revised from $35 to $32.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Cline Christopher R. sold 20,000 shares for $35.01 per share. The transaction valued at 700,202 led to the insider holds 92,083 shares of the business.
CHRISTOPHER CLINE bought 20,000 shares of TVTX for $700,200 on Dec 01 ’25. On Nov 04 ’25, another insider, Calvin Sandra, who serves as the SVP, CHIEF ACCOUNTING OFFICER of the company, sold 67,115 shares for $36.00 each. As a result, the insider received 2,416,140 and left with 48,545 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 3076058624 and an Enterprise Value of 3151277568. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.06 while its Price-to-Book (P/B) ratio in mrq is 41.81. Its current Enterprise Value per Revenue stands at 7.231 whereas that against EBITDA is -89.952.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.86, which has changed by 0.9268565 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $37.50, while it has fallen to a 52-week low of $12.91. The 50-Day Moving Average of the stock is 9.41%, while the 200-Day Moving Average is calculated to be 60.69%.
Shares Statistics:
According to the various share statistics, TVTX traded on average about 2.10M shares per day over the past 3-months and 1428640 shares per day over the past 10 days. A total of 89.46M shares are outstanding, with a floating share count of 87.73M. Insiders hold about 1.95% of the company’s shares, while institutions hold 116.69% stake in the company. Shares short for TVTX as of 1764288000 were 10969722 with a Short Ratio of 5.22, compared to 1761868800 on 10879506. Therefore, it implies a Short% of Shares Outstanding of 10969722 and a Short% of Float of 12.350000399999999.
Earnings Estimates
The stock of Travere Therapeutics Inc (TVTX) is currently in the spotlight, with 7.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.07, with high estimates of $0.23 and low estimates of -$0.07.
Analysts are recommending an EPS of between $1.06 and $0.53 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is $1.82, with 7.0 analysts recommending between $2.98 and $0.73.
Revenue Estimates
According to 13 analysts,. The current quarter’s revenue is expected to be $143.04M. It ranges from a high estimate of $184M to a low estimate of $122.37M. As of. The current estimate, Travere Therapeutics Inc’s year-ago sales were $74.79MFor the next quarter, 13 analysts are estimating revenue of $133.51M. There is a high estimate of $144.7M for the next quarter, whereas the lowest estimate is $119.57M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $545M, while the lowest revenue estimate was $483.41M, resulting in an average revenue estimate of $503.75M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $691.8M in the next fiscal year. The high estimate is $802.8M and the low estimate is $580M.
